Last reviewed · How we verify
Apatinib and PD1
Apatinib and PD1 is a Small molecule drug developed by Henan Cancer Hospital. It is currently in Phase 2 development.
Apatinib is an anti-angiogenesis inhibitor used in combination with SHR-1210 (a PD-1 antibody) to treat various cancers, including small-cell lung cancer, hepatocellular carcinoma, and non-small cell lung cancer. Apatinib has also been studied in combination with Camrelizumab (another PD-1 antibody) for the treatment of certain cancers, such as AFP gastric or gastroesophageal junction adenocarcinoma.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Apatinib and PD1 |
|---|---|
| Sponsor | Henan Cancer Hospital |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Aspartate aminotransferase increased
- Platelet count decreased
- Alanine aminotransferase increased
- White blood cell count decreased
- Proteinuria
- Hypertension
- Neutrophil count decreased
- Palmar-plantar erythrodysaesthesia syndrome
- Blood bilirubin increased
- Asthenia
- Anaemia
- Diarrhoea
Key clinical trials
- A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE) (PHASE2)
- Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC) (PHASE2)
- A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy (PHASE3)
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (PHASE2)
- Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer (PHASE2)
- Neoadjuvant Therapy for Locally Advanced Colon Cancer (PHASE2)
- Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection (PHASE1, PHASE2)
- Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Apatinib and PD1 CI brief — competitive landscape report
- Apatinib and PD1 updates RSS · CI watch RSS
- Henan Cancer Hospital portfolio CI
Frequently asked questions about Apatinib and PD1
What is Apatinib and PD1?
Who makes Apatinib and PD1?
What development phase is Apatinib and PD1 in?
What are the side effects of Apatinib and PD1?
Related
- Manufacturer: Henan Cancer Hospital — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing